GleamWall
中文EN

ISPC iSpecimen Inc.

Services-Commercial Physical & Biological Research · Nasdaq · SEC CIK 1558569 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-82.0%
TTM net income YoY5.9%
TTM EPS YoY180.8%
Revenue 3-yr CAGR-61.2%
Net income 3-yr CAGR—

Margins

Gross margin-10.3%
Operating margin-1,455.3%
Net margin-1,797.3%
FCF margin—
EBITDA margin-1,364.6%

Returns

ROE-303.9%
ROA-116.1%
ROIC (approx.)—
Asset turnover0.06x

Leverage & solvency

Liabilities / assets58.1%
Debt / equity0.00x
Current ratio1.16x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.71x
Accruals ratio-34.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$1.93M$9.29M
Cost of revenue$1.71M$5.11M
Gross profit$215,665$4.18M
R&D expense—$1.49M
SG&A expense$3.47M$6.07M
Operating income-$8.98M-$12.73M
Interest expense$1,949$173,771
Net income-$10.49M-$12.50M
EBITDA-$7.25M-$10.43M
EPS (basic)-2.28-17.58
EPS (diluted)-2.28-17.58
Weighted avg. shares (diluted)4.60M710,852
Balance sheet
Cash & equivalents$6.88M$1.88M
Receivables$48,298$1.44M
Inventory—$45,110
Current assets$6.95M$3.59M
PP&E, net$25,543$93,563
Total assets$9.53M$9.35M
Current liabilities$6.23M$5.77M
Total liabilities$6.44M$6.04M
Shareholders' equity$3.09M$3.31M
Shares outstanding211,9761.70M
Cash flow statement
Operating cash flow-$4.24M-$8.26M
Capital expenditure$454$31,546
Free cash flow-$4.24M-$8.30M
Investing cash flow-$1.00M$1.98M
Financing cash flow$10.24M$5.82M
Depreciation & amortization$1.73M$2.29M
Stock-based compensation$21,266$249,675

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.